Crossref
‘A sigh of relief’: New malaria drug succeeds in clinical trial as existing treatments falter
Science · 2025
DOI: 10.1126/science.aee0352 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, 2025. Verfasst von Kai Kupferschmidt. Beteiligte Einrichtung: Toronto. Hauptthemen laut MEDLINE: Antimalarials, Malaria, Malaria, Falciparum, Plasmodium falciparum.
Abstract (Originalsprache)
Ganaplacide, developed by Novartis, eases worries about drug resistance—but hard choices loom on how to use it
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
AntimalarialsMalariaMalaria, FalciparumPlasmodium falciparumImidazolesPiperazinesDrug DevelopmentHumansClinical Trials as TopicDrug ResistanceTanzania
Substanzen
AntimalarialsganaplacideImidazolesPiperazines
Autor:innen und Institutionen
- Toronto.
Zitieren
APA
Kupferschmidt, K. (2025). ‘A sigh of relief’: New malaria drug succeeds in clinical trial as existing treatments falter. Science. https://doi.org/10.1126/science.aee0352
Vancouver
Kupferschmidt K. ‘A sigh of relief’: New malaria drug succeeds in clinical trial as existing treatments falter. Science. 2025. doi:10.1126/science.aee0352
BibTeX
@article{Kupferschmidt2025,
author = {Kupferschmidt, Kai},
title = {‘A sigh of relief’: New malaria drug succeeds in clinical trial as existing treatments falter},
journal = {Science},
year = {2025},
doi = {10.1126/science.aee0352}
}
EUVIMED